Abstract: An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Abstract: An antibody or antigen binding fragment thereof that binds to an IL-36, wherein the antibody or antigen binding fragment thereof binds to both IL-36? and IL-36?, and wherein the antibody is an antagonist of both IL-36? and IL-36?.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Abstract: The present invention relates to the formation of emulsions using small amphipathic molecules, such as peptides which self-assemble to form an interface between at least two substantially immiscible liquids. The emulsions may find application is a variety of technological fields, such as in food, cosmetics, life style products, coating, catalysis, encapsulation, drug delivery and/or cell assays. There is also provided a method of making such emulsions, as well as methods of tailoring the stability of the emulsions for particular applications.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

Abstract: The present invention provides an abdominal restraint for use in medical and surgical procedures that is specially adapted for restraining an abdominal pannus and exposing the groin area of a patient. The abdominal restraint of the present invention includes a base member and a support member that is selectively attachable to the base member. Alternatively, the abdominal restraint of the present invention includes a lateral member that is selectively attachable to at least one longitudinal member, which in turn may be attached to an operating or examining table. In its various embodiments, the present invention discloses a number of designs for the safe and efficient restraint of an abdominal pannus.

Abstract: A process in which a salt of clavulanic acid, typically an amine salt or an alkali metal salt is exposed to conditions, particularly a pH of less than 6.0, which reduces the quantity of contaminating impurities. The process may be a washing process, a recrystallisation process or a preparative process.

Abstract: The present invention provides an abdominal restraint for use in medical and surgical procedures that is specially adapted for restraining an abdominal pannus and exposing the groin area of a patient. The abdominal restraint of the present invention includes a base member and a support member that is selectively attachable to the base member. Alternatively, the abdominal restraint of the present invention includes a lateral member that is selectively attachable to at least one longitudinal member, which in turn may be attached to an operating or examining table. In its various embodiments, the present invention discloses a number of designs for the safe and efficient restraint of an abdominal pannus.

Abstract: A process in which a salt of clavulanic acid, typically an amine salt or an alkali metal salt is exposed to conditions, particularly a pH of less than 6.0, which reduces the quantity of contaminating impurities. The process may be a washing process, a recrystallisation process or a preparative process.

Abstract: An optically addressed, optical relaying device placed between crossed polarizers utilizes an array of pixels made up of photodetectors, circuitry, and modulating pads, and an analog liquid crystal to modulate the intensity of an optical signal on a pixel by pixel basis. The photodetector generates a current proportional to the light detected. Once the current exceeds a certain level, the circuitry stores a charge on the modulating pad proportional to the photo-induced current. This stored charge rotates the molecules of the liquid crystal thereby rotating the polarization of the light signal. The output polarizer then attenuates the light beam according to the change in polarization.

Abstract: A variable-ratio power transmission mechanism having two output shafts for driving respective wheels or tracks at opposite sides of a heavy off-the-road vehicle, and having a steering mechanism for varying the relative rotational speeds of said shafts, is known. Where the steering mechanism includes a null shaft which is not driven when straight-line travel is required, said shaft has been driveable by hydrostatic means, but these have sometimes proved unreliable. It is therefore proposed to drive the null shaft by mechanical two-speed gearing driven from the input of the power transmission mechanism. The null shaft is selectively driveable by said gearing in either direction of rotation through the appropriate one of two progressively engaging clutches until it attains a first speed, and an epicyclic reduction gear in said gearing is then locked up to drive the null shaft in the same direction at a higher speed.